Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Warren

Showing results (201-210 of 1,117) with videos related to

Pageof 112
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|August 20, 2014
Impact factor for 2013C Warren Olanow, Jose A Obeso
The American Journal of Dermatopathology|August 1, 1990
Congenital palpebral lipoblastoma. First report of a caseM H Enghardt, R C Warren
Journal of the National Medical Association|January 9, 2016
The Search for the Legacy of the USPHS Syphilis Study at Tuskegee. Lexington 2011Ralph V Katz, Rueben C Warren
Movement Disorders : Official Journal of the Movement Disorder Society|November 24, 2021
Parkinson's Disease Modification Through Abl Kinase Inhibition: An OpportunityMilton H Werner, C Warren Olanow
Comprehensive Therapy|December 1, 1987
Diagnosis and treatment of primary hyperparathyroidismF J Palmer, M C Warren
Movement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
Levodopa therapy for Parkinson's disease: challenges and future prospectsC Warren Olanow, Andrew Lees, Jose Obeso
Annals of Neurology|January 8, 2009
Drug selection and timing of initiation of treatment in early Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Chemsuschem|May 12, 2023
Reconsidering Anode Materials for Fluoride-Ion Batteries-The Unexpected Roles of Carbide FormationDon McTaggart, Scott C Warren, Oliver Clemens
Annals of Neurology|April 1, 2003
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Neurobiology of Aging|October 7, 2005
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's diseaseKevin St P McNaught, C Warren Olanow
Pageof 112

Showing results (201-210 of 1,117) with videos related to

Sort By:
Pageof 112
Movement Disorders : Official Journal of the Movement Disorder Society|August 20, 2014
Impact factor for 2013C Warren Olanow, Jose A Obeso
The American Journal of Dermatopathology|August 1, 1990
Congenital palpebral lipoblastoma. First report of a caseM H Enghardt, R C Warren
Journal of the National Medical Association|January 9, 2016
The Search for the Legacy of the USPHS Syphilis Study at Tuskegee. Lexington 2011Ralph V Katz, Rueben C Warren
Movement Disorders : Official Journal of the Movement Disorder Society|November 24, 2021
Parkinson's Disease Modification Through Abl Kinase Inhibition: An OpportunityMilton H Werner, C Warren Olanow
Comprehensive Therapy|December 1, 1987
Diagnosis and treatment of primary hyperparathyroidismF J Palmer, M C Warren
Movement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
Levodopa therapy for Parkinson's disease: challenges and future prospectsC Warren Olanow, Andrew Lees, Jose Obeso
Annals of Neurology|January 8, 2009
Drug selection and timing of initiation of treatment in early Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Chemsuschem|May 12, 2023
Reconsidering Anode Materials for Fluoride-Ion Batteries-The Unexpected Roles of Carbide FormationDon McTaggart, Scott C Warren, Oliver Clemens
Annals of Neurology|April 1, 2003
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Neurobiology of Aging|October 7, 2005
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's diseaseKevin St P McNaught, C Warren Olanow
Pageof 112